Modifications to Prostate Cancer Diagnosis following COVID-19 and Following Models
Oncology Research and Treatment · 2025
DOI: 10.1159/000544977 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research and Treatment, 2025. Verfasst von Miroslav Stojadinovic und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Clinic of Urology and Nephrology, Clinical Centre of "Kragujevac", Kragujevac, Serbia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Introduction
The COVID-19 pandemic has impacted the treatment of prostate cancer (PCa). The study examines any predictions that could point to future models.
Methods
Two interrupted time series analyses were conducted: one for the pre-COVID period (January 2017 to December 2019) and another for the post-COVID period during 2022. Information on age, total prostate-specific antigen (PSA), abnormal digital rectal exam (DRE), prostate volume, previous negative biopsy, number of positive biopsies, Gleason score, and biopsy outcome were collected for all patients. The categories for the results were no cancer, insignificant, low and intermediate, high-risk, and very high-risk PCa. Using a generalized linear model (GLM), the outcomes are modeled. The area under the curve (AUC) and accuracy were used to assess how well multi-class predictions performed.
Results
Overall, 244 patients who had biopsies following the COVID-19 pandemic and 832 patients who had biopsies before the pandemic were compared. The accuracy of the GLM was only 0.635. The AUC for categories no-cancer, low- and intermediate-risk, and very high-risk patients was 0.821, 0.716, and 0.926. With scaled relevance values, PSA was the most critical test. The two features that significantly influenced the treatment model prediction for PCa were biopsy PSA level and DRE, respectively.
Conclusion
Advanced age and a very high-risk group appear to have a detrimental impact on the results of biopsies conducted after the first wave of the COVID-19 era. At the same time, PSA levels and abnormal DRE are the most significant predictors in GLM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Clinic of Urology and Nephrology, Clinical Centre of "Kragujevac", Kragujevac, Serbia.
- Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
- Clinic for Nephrology, University Clinical Center of Serbia, Belgrade, Serbia, dr.milorad.stojadinovic@gmail.com.
- Pharmacology and Toxicology Department, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Zitieren
APA
Stojadinovic, M., Stojadinovic, M., & Jankovic, S. (2025). Modifications to Prostate Cancer Diagnosis following COVID-19 and Following Models. Oncology Research and Treatment. https://doi.org/10.1159/000544977
Vancouver
Stojadinovic M, Stojadinovic M, Jankovic S. Modifications to Prostate Cancer Diagnosis following COVID-19 and Following Models. Oncology Research and Treatment. 2025. doi:10.1159/000544977
BibTeX
@article{Stojadinovic2025,
author = {Stojadinovic, Miroslav and Stojadinovic, Milorad and Jankovic, Slobodan},
title = {Modifications to Prostate Cancer Diagnosis following COVID-19 and Following Models},
journal = {Oncology Research and Treatment},
year = {2025},
doi = {10.1159/000544977}
}
EUVIMED